BMC
Cancer

RESEARCH ARTICLE   **Open Access**

MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis

Wenjia Wang[1,2†], Jinhui Li[1,3†], Wei Zhu[3], Chen Gao[1], RuiJingfang Jiang[1,4], Wenxue Li[3], Qiansheng Hu[1*] and Bo Zhang[1*]

Abstract

Background: MicroRNA-21 (miR-21) has been suggested to play a significant role in the prognosis of carcinoma. The recognition of novel biomarkers for the prediction of cancer outcomes is urgently required. However, the potential prognostic value of miR-21 in various types of human malignancy remains controversial. The present meta-analysis summarises and analyses the associations between miR-21 status and overall survival (OS) in a variety of tumours.

Methods: Eligible published studies were identified by searching the PubMed and Chinese Biomedicine databases. The patients' clinical characteristics and survival results were pooled, and a pooled hazard ratio (HR) with 95% confidence intervals (95% CI) was used to calculate the strength of this association. A random-effects model was adopted, and then, meta-regression and subgroup analyses were performed. In addition, an analysis of publication bias was also conducted.

Results: Twenty-seven eligible articles (including 31 studies) were identified that included survival data for 3273 patients. The pooled HR suggested that high miR-21 was clearly related to worse overall survival (HR = 2.27, 95% CI: 1.81-2.86), with a heterogeneity measure index of $I^2 = 76.0\%$, $p = 0.001$, showing that miR-21 might be a considerable prognostic factor for poor survival in cancer patients.

Conclusions: MiR-21 might be a potentially useful biomarker for predicting cancer prognosis in future clinical applications.

Keywords: miR-21, Cancer, Prognosis, Meta-analysis

Background

MicroRNAs (miRNAs) are a class of endogenous, small (approximately 22 nucleotides), non-coding, highly conserved and single-stranded RNAs that negatively regulate mRNA and protein expression by forming base-pairs with target mRNAs and sequentially induce translational repression and mRNA cleavage [1,2]. More than 50% of miRNA genes are frequently located at fragile sites and genomic regions involved in multiple cancers, which suggests their potentially important and complex role in cancer [3]. Previous studies have showed that miRNAs are involved in regulating many urgent biological processes, such as cellular differentiation, proliferation, metabolism,

cell-cycle control, development, apoptosis and tumour development [4,5]. It has been reported that if the target gene of the miRNA is a tumour suppressor or oncogene, the aberrant expression of the miRNA will lead to disruptions in the miRNA-target genes and induce a disease status and even cancer development [6].

MiR-21 stands out as the most commonly dramatically up-regulated miRNA in both solid and haematological malignancies [7], and it is associated with clinicopathological factors in a considerable proportion of human malignancies [8-15]. In addition, extensive studies have implicated its integral role in tumour pathogenesis and during all other stages of carcinogenesis. Some studies have confirmed that miR-21 down-regulates four tumour suppressor genes: maspin, programmed cell death 4 (PDCD4), tropomyosin1 (TPM1) and phosphatase and tensin homolog (PTEN), which are all involved in tumourigenesis, cell

---

* Correspondence: huqsh@mail.sysu.edu.cn; zhangb65@mail.sysu.edu.cn
†Equal contributors
[1]Department of Preventive Medicine, School of Public Health, Sun Yat-sen University, Zhongshan II Road, Guangzhou 510080, PR China
Full list of author information is available at the end of the article

cycle control, apoptosis and metastasis [16-20]. There is some evidence that indicates that the level of miR-21 expression is significantly associated with the prognosis of tumour patients, suggesting that it might serve as a prognostic marker for human malignancy [21].

Prognostic factors may identify subsets of patients with a worse prognosis and facilitate the selection of a more aggressive treatment strategy. The discovery of molecular biological prognostic factors would be helpful in a more accurate prediction of clinical outcome and may also reveal novel predictive factors and therapeutic targets [22]. However, the existing prognostic and predictive factors still need more proof, and they should be applied with caution when choosing the optimal adjuvant treatment. It is of great importance to balance the threshold of determining if patients need further treatment to avoid overtreatment or insufficient treatment. The prognostic role of miR-21 might potentially enhance the preoperative selection of low-risk patients who can be treated with resection alone, while directing high-risk cases to systemic treatment [23]. Above all, due to the apparent difference in expression between normal and malignant tissue and its causal role in cancer development, miR-21 is currently attracting considerable attention and has led to a number of studies reporting the relationship between miR-21 status and clinical outcomes among a wide variety of tumour types. However, most studies were conducted with a small sample size, and the observed associations were discordant. Therefore, we performed a literature-based meta-analysis of eligible studies to produce evidence-based results on the prognostic role of miR-21 in multiple types of malignant tumours to clarify this question and identify further research needs.

Methods
We performed this meta-analysis according to the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [24] and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) [25].

Search strategy and selection criteria
Studies were identified via an electronic search of PubMed and Chinese Biomedicine databases using the following keywords: (microRNA-21 OR miR-21 OR miR-21 OR mir21) AND (prognosis OR prognostic OR outcome OR mortality OR survival). The search ended on June 19th, 2014, and no lower date limit was used. The search was performed without language restriction. We also contacted some of the authors of the identified studies to obtain some unavailable data. Reference lists from relevant primary studies and review articles were also scanned for additional relevant publications. To ensure the quality of

the meta-analysis, two authors (Li Jinhui & Wang Wenjia) independently performed the search and identification according to the standardised approach, and the final selection of a study for inclusion in the meta-analysis was reached by consensus.

To be eligible for inclusion, studies met the following criteria: (I) they reported research on patients with any type of carcinoma; (II) they measured the expression of miR-21 and reported the corresponding cut-off value; (III) they investigated the association between miR-21 expression and overall survival (OS); (IV) the hazard ratio (HR) for overall survival according to miR-21 status either had to be reported or could be calculated from the information presented; (V) the study sample size was higher than twenty individuals; (VI) when the same author or group reported results obtained from the same patient population in more than one article, the most recent report or the most informative one was included in this analysis to avoid overlapping between cohorts; and (VII) they used tissue samples (without any neoadjuvant therapy) obtained from surgically resected tumours and corresponding non-cancerous or normal tissues for comparison.

Definition, data extraction and methodological assessment
Overall survival was defined as the interval between the medical treatment and the death of patients or the last observation.

All eligible publications were reviewed by two reviewers (Li Jinhui & Wang Wenjia), and they then extracted the study data based on a predefined standardised form including the characteristics of eligible studies, the baseline information of patients and the survival analysis data (Additional file 1: Table S1). Disagreements were resolved by discussion. The extracted information was summarised in a consistent manner to prevent bias. Survival outcome data were synthesised using the time-to-event hazard ratio (HR) and the 95% confidence intervals (95% CI) from the original article as the effective measure. If this information was not available, sending an email to the authors for complementary information was our first choice. If the Kaplan-Meier survival curves were available, we used the method previously described by Parmar et al. and Tierney et al. to estimate HR and its corresponding 95% CI [26]. Additional data were extracted from the studies, including the first author, publication year, number of patients, mean age, follow-up, cancer type (system), cancer category and stage.

Furthermore, a methodological assessment of each study was also conducted by two investigators (Li Jinhui & Wang Wenjia) according to REMARK guidelines [27]. Disagreements were adjudicated by a third investigator (Zhu Wei) after referring to the original articles.

Statistical analysis

To quantitatively combine the survival data, we extracted the HRs and their 95% CIs to assess the impact of the miR-21 status on tumour prognosis. A combined HR > 1 implied a worse survival for the group with miR-21 overexpression. This negative impact of miR-21 on survival was considered statistically significant if the 95% CI for the combined HR did not overlap 1. To assess heterogeneity among the studies, we used I^2 statistics, which describe the proportion of total variation in meta-analysis estimates due to between-study heterogeneity. The variation is measured from 0-100%, with increasing I^2 values indicating a larger impact of between-study heterogeneity in the meta-analysis [28]. The results were considered statistically significant if the p value was less than 0.05 and was quantified using the I^2 metric ($I^2 <$ 25%, no heterogeneity; $I^2 = $ 25-50%, moderate heterogeneity; and $I^2 > $ 50%, strong heterogeneity) [29]. If heterogeneity was found, the random-effects model was applied. Otherwise, the fixed-effects model was used. In addition, we also investigated potential sources of heterogeneity through meta-regression analysis and subgroup analysis. Sensitivity analyses were performed with the exclusion of studies that had the highest weight, the highest or lowest estimates, the largest sample size, or the studies for which data were acquired through calculation. The Begg's funnel plot method was used to investigate any possible publication bias. For all analyses, a two-sided p value less than 0.05 was considered to be statistically significant. All analyses were performed using STATA version 12.0 software (Stata Corporation, College Station, TX).

Results

Literature selection and characteristics

A total of 288 potentially relevant citations, including 256 reports in English and 32 in Chinese, were retrieved after the initial database search using the search strategies described previously. The titles and abstracts of relevant articles were read by two authors independently. A total of 185 citations were excluded from analysis after the first screening based on abstracts or titles (39 were review articles; 25 were irrelevant to cancer; 54 dealt with cell lines or animals; 41 were irrelevant to prognosis; 14 did not study tumour tissues; 12 were unrelated to miR-21), leaving 103 citations for further full text evaluation. Upon further review, 73 articles were eliminated (29 described survival analysis of miR-21 with DFS, RFS or CSS; 17 did not give sufficient survival data; 2 had the overlapping data sets; 3 had a very small sample size; 4 lacked full text; 18 detected miR-21 expression the index from serum or plasma). Then after sensitive analysis as follows, three publications were removed. As a result, 27 eligible studies [11,13,30-55]

including 31 cases were included for the final analysis. The flow chart for the studies is shown in Figure 1.

The basic characteristic descriptions of the 36 eligible studies are summarised in Table 1. Briefly, these studies were conducted in 11 countries (13 cohorts were Asian populations and 18 cohorts were European and American populations, and they were published between 2003 and 2014. Study sample sizes ranged from 25 to 345 patients (median sample size, 105.5 patients). A total of 18 cohorts were of I-IV stage or of all stages. Most studies investigated miR-21 by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Overall, 21 cohorts reported miR-21 as an indicator of poor prognosis, while the other 10 showed no significant impact of miR-21 on overall survival.

Quality assessment and meta-analysis

REMARK was used a guideline rather than a scoring scale, so the assessment was a qualitative process rather than a quantitative one (Additional file 2: Table S2). Instead of grading every published report and ranking their quality as "high" or "low", we carried out an assessment emphasising the analysis and presentation of the studies to prevent the inclusion of inferior data which would influence the accuracy of the meta-analysis. Two studies were eliminated during this procedure due to their small sample size and poor quality of data [12,59]. In addition, when using the random-effects model due to the significant heterogeneity of the studies, dismal survival outcomes were observed for tumour patients with miR-21 overexpression. The pooled HRs and CIs were 2.27(1.81-2.86), with I^2 values of 76.0%, and Figure 2 shows the results of the forest plot explained above.

Assessment of heterogeneity and subgroup analysis

Highly significant heterogeneity was detected when all studies were pooled ($I^2 = $ 76.0%), signifying that the variation was due to heterogeneity rather than chance. To make a conservative estimate, a random-effect model rather than a fixed-effect model was used to account for the highly significant inter-study heterogeneity to summarise the prognostic value of miR-21 across studies. When all study populations were combined, dismal survival outcomes were observed with the overexpression of miR-21 (Figure 2). There was evidence of significant inter-study heterogeneity ($p = $ 0.001, $I^2 = $ 76.0%).

Considering the substantial heterogeneity exhibited in the trials aggregated with respect to the overall survival, meta-regression and subgroup analyses were conducted to explore the heterogeneity of the covariates including the publication year, study location, number of patients, mean age, follow-up, cut-off value of miR-21, cancer category and stage (Table 2). Ultimately, the study age might be a source of heterogeneity (Adj $R^2 = $ 10.63%).

288 papers were retrieved (256 in English and 32 in Chinese) and their titles and abstracts were reviewed

Articles were excluded due to:

① 39 (25Eng+14Chin) were review articles
② 25 (23Eng+2Chin) were irrelevant to cancer
③ 54 (46Eng+8Chin) were dealt with cell lines
④ 41 (34Eng+8Chin) were irrelevant to prognosis
⑤ 14 Eng were of genetic variation
⑥ 12 Eng were unrelated to miR-21

103 full texts were reviewed

Articles were excluded due to:

① 29 Eng were for the survival analysis of miR-21 with DFS, RFS or CSS
② 17 Eng didn't give sufficient survival data
③ 2 Eng had overlapping data sets
④ 3 Eng were with very small sample sizes (<20 patients)
⑤ 4 Eng were lacked of full-texts
⑥ 18 Eng detected Mir21 from serum or plasma
⑦ 3 Eng were removed after sensitive analysis

27 articles (including 31 studies) were included in the meta-analysis

Figure 1 Flow diagram illustrating the screening and selection process.

The results showed that combined HR of the Asian population was 2.27(1.81,2.86) with $I^2 = 76.0\%$. We also tried to use other grouping terms to explore the prognostic role of miR-21, such as TNM stage, publication year, CEA (cut-off value) *et al*. However, no clinical significance could be found.

Sensitivity analysis and publication bias

The Begg's funnel plot method was applied to detect publication bias in the meta-analysis. No bias was found in any of the included studies (p =0.174) (Figure 3). In addition, sensitivity analysis was also conducted (Additional file 3: Figure S1), and we found that when three studies with four cases [34,40,54] were discarded, the outcome of the sensitivity analysis was more stable.

Discussion

Accurate prognostic factors and their predictive functions are particularly valuable in patients with some specific types of cancer which have widely varying outcomes and for which systemic adjuvant therapy might be important. The differentiation of high-risk patients from low-risk patients may help us make a sensible decision to balance treatment with further adjuvant therapy and the toxic

side-effects inflicted on patients [60]. MiR-21 is an exciting potential new biomarker of prognosis in malignancies, and molecular studies have been encouraging. While some studies found that miR-21 was significantly associated with patient survival, other studies did not find any significant results for miR-21.

Although a similar meta-analysis on the prognostic value of miR-21 in various types of cancer was reported three years ago [61], there were several problems with the analysis that adversely impacted its quality. First, this study did not describe the heterogeneity among the eligible studies, while the between-study heterogeneity would have a profound influence on the validity of the conclusion. Second, the up-regulation of miR-21 was found in both tumour tissues and non-tumour tissues such as plasma and serum; however, in the absence of a proven correlation between these two sources of tissues, it is not rational to combine their results together without any explanation or discussion [62]. Third, one eligible study emphasised the interaction and combined effect of miR-21 and other factors instead of the independent role of miR-21 in prognosis [63]. In addition, numerous studies on the association between miR-21 and prognosis have emerged since this meta-analysis

Table 1 Baseline characteristics of the eligible studies evaluating miR-21 expression and OS

Study & year	Cancer	Cancer type (system)	Sample size	Country	Stage	Age	Follow-up (months)	Comparisons	Cut off value	Method
Nagao 2012 [17]	PDAC	Other	79	Japan	I-IV	65	40	NG	Mean	qRT-PCR
Shibuya 2010 [31]	CRC	Digestive	156	Japan	*A-D	65	60	Normal tissues&	Mean	qRT-PCR
Gao 2010 [11]	NSCLC	Respiratory	47	China	I-III	64	60	Normal tissues	Median	qRT-PCR
Childs 2009 [32]	HNSCC	Other	104	USA	I-IV	60	60	Normal tissues	Mean	qRT-PCR
Yan 2008 [33]	BC	Breast	113	China	I-III	48	66.2	Normal tissues	Mean	qRT-PCR
Lee 2011 [35]	BC	Breast	109	Korea	I-III	48	100	NG	Mean	qRT-PCR
Jiang 2011 [36]	Melanoma	Other	106	China	I-IV	60	60	NG	Median	qRT-PCR
Zhi 2010 [37]	Astrocytoma	Other	124	China	I-IV	47.8	35.2	NG	Median	qRT-PCR
Jamieson 2012 [38]	PDAC	Other	58	UK	II,III	65	23.9	Normal tissues	Median	qRT-PCR
Schetter 2008 [39]	CRC	Digestive	84	USA	I-IV	64.6	68.0	Normal tissues	Highest tertile	qRT-PCR
Schetter 2008 [39]	CRC	Digestive	113	HK	I-IV	55.8	84.6	Normal tissues	Dichotomize	Microarray
Faltejskova 2012 [41]	CRC	Digestive	44	Czech	I-IV	67	84	Normal tissues	Median	qRT-PCR
Chen 2013 [42]	CRC	Digestive	195	Taiwan	I-IV	66	60	Normal tissues	Mean	qRT-PCR
Toiyama 2013 [43]	CRC	Digestive	186	Japan	I-IV	67	60	Normal tissues	0.0031	qRT-PCR
Markou 2008 [13]	NSCLC	Respiratory	48	USA	I-IV	60	50	Healthy controls	2-fold	qRT-PCR
Liu2012 [44]	NSCLC	Respiratory	70	China	I-IV	60	30	Healthy controls	2-fold	qRT-PCR
Saito2011 [45]	NSCLC	Respiratory	89	USA	I-III	63.6	80	Normal tissues	Median	qRT-PCR
Saito2011 [45]	NSCLC	Respiratory	37	Norway	I-III	64.4	80	Normal tissues	Median	qRT-PCR
Saito2011 [45]	NSCLC	Respiratory	191	Japan	I-III	59.6	80	Normal tissues	Median	qRT-PCR
Markou 2013 [46]	NSCLC	Respiratory	48	Greece	I-IV	60	40	Normal tissues	6.3-fold	qRT-PCR
Wu2013 [56]	Glioma	Other	152	China	I-IV	45.1	60	Normal tissues	Mean	qRT-PCR
Papaconstantinou2012 [57]	PC	Other	88	Greece	I-IV	66.5	40	Normal tissues	Mean	qRT-PCR
Karakatsanis2011 [48]	HCC	Digestive	60	Greece	I-IV	60	50	Healthy controls	Mean	qRT-PCR
Kadera2013 [49]	PDAC	Other	153	USA	I, II,IV	65	42	Healthy controls	Median	ISH
Markou 2014 [58]	BC	Breast	112	Greece		60	75	Normal tissues	Median	qRT-PCR
Akagi2013 [50]	LC	Respiratory	67	USA	I	64.9	60	Normal tissues	Median	qRT-PCR
Akagi2013 [50]	LC	Respiratory	25	Norway	I	64.0	60	Normal tissues	Median	qRT-PCR
Bovell2013 [51]	CC	Digestive	345	USA	IV	65	17	Normal tissues	Mean	qRT-PCR

Table 1 Baseline characteristics of the eligible studies evaluating miR-21 expression and OS (Continued)

Capodanno 2013 [52]	NSCLC	Respiratory	80	Italy	I-IV	67	32	Normal tissues	Median	qRT-PCR
Faragalla2012 [53]	RCC	Digestive	121	Canada	I-III	62.4	52.8	Normal tissues	40th percentile	qRT-PCR
Mathe 2009 [55]	ESCC	Digestive	69	Two countries	I-IV	62	62.5	Normal tissues	Dichotomize	qRT-PCR

Abbreviations: PDAC pancreatic ductal adenocarcinoma, CRC colorectal cancer, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, CC colon cancer, RC rectal cancer, HCC hepatocellular carcinoma, ESCC oesophageal squamous cell carcinoma, BC breast cancer, PC pancreatic cancer, RCC renal cell carcinoma, *Duke's stage, ISH In Situ Hybridization, NG Not given, &Adjacent noncancerous tissues were procured from patients.

was published. As described above, carrying out a new systematic review and meta-analysis on this issue was deemed essential. We were able to conduct our meta-analysis on a larger sample size and with a more appropriate method to accurately evaluate the role of miR-21 in the prognosis of cancer.

When we stratified the studies according to the different possible contributors through meta-regression and subgroup analysis, none of the studies had a definitive explanation for the heterogeneity. Generally, the high degree of heterogeneity was probably due to the difference in the baseline characteristics of the included


Figure 2 Meta-analysis of the association between miR-21 expression and prognosis. Meta-analysis of the forest plot showing the association between miR-21 and overall cancer survival. The squares represent the size of the study and are centred on the HR. The whiskers represent the 95% CIs. A random effects (RE) model was used, and the x-axis shows the Hazard ratio.

Table 2 Meta-regression and subgroup analysis of the studies reporting the association between microRNA-21 and the overall survival of cancer patients

Stratified study	No. of studies	Pooled HR(95% CI)		Meta-regression			Heterogeneity	
		Fixed-Model	Random-Model	Tau^2	Adj R^2 (%)	*p*-value	I^2 (%)	*p*-value
Year				0.246	3.79	0.350		
>2012	17	2.48(2.17,2.83)	2.46(2.02,2.99)				43.0	0.031
≤2012	14	1.53(1.29,1.81)	2.13(1.36,3.31)				83.3	0.001
CEA (cut-off value)				0.268	−4.75	0.848		
Mean & Median	25	2.06(1.84,2.30)	2.31(1.77,3.03)				80.4	0.001
Others	6	2.11(1.53,2.92)	2.11(1.53,2.92)				0.0	0.822
Sample size				0.268	−4.48	0.216		
>100	15	1.85(1.53,2.22)	2.53(1.59,4.02)				82.1	0.001
<=100	16	2.18(1.92,2.48)	2.12(1.67,2.69)				66.4	0.001
Race				0.260	−1.68	0.537		
Yellow	12	2.63(2.26,3.07)	2.67(2.07,3.42)				50.9	0.021
White	18	1.63(1.41,1.88)	1.94(1.40,2.71)				78.7	0.001
Age				0.229	10.63	0.391		
<=60	12	2.42(2.08,2.82)	2.52(2.08,3.06)				32.2	0.088
>60	19	1.80(1.56,2.07)	1.90(1.21,3.01)				87.9	0.001
TNM stage				0.263	−2.78	0.362		
I-IV	17	1.98(1.76,2.23)	2.16(1.16,2.92)				80.3	0.001
Others	14	1.22(1.15,1.30)	1.86(1.53,2.26)				80.7	0.001
Cancer category				0.258	−0.55	0.421		
Digestive system	13	2.35(1.96,2.81)	2.43(1.95,3.03)				28.1	0.162
Respiratory system	11	1.82(1.47,2.26)	2.08(1.40,3.08)				66.9	0.001
Breast cancer	3	3.07(1.88,5.01)	4.08(1.23,13.48)				81.4	0.005
Others systems	4	1.89(1.60,2.25)	1.68(0.76,3.73)				95.0	0.001
Detect Method				0.270	−5.34	0.686		
qPCR	29	2.27(1.81,2.86)	2.07(1.86,2.29)				76.0	0.001
others	2	————	————	————	————	————		
Overall	31	2.07(1.86,2.29)	2.27(1.81, 2.86)				76.0	0.001

Abbreviations: CI confidence interval, HR hazard ratio.

patients (age, histological type, differentiation or tumour stage, race or location, the sample size, the detection methods and the duration of follow-up). In addition, the lack of detailed information about baseline characteristics as a result of non-standardised reporting likely contributed to diversity across the studies as well. Moreover, studies that do not extend their analysis beyond univariate survival analysis are therefore less valuable because these confounders between miR-21 and OS did not distribute equally in each group for the variations in author's clinical experience, adjustment method and the innate characteristics of different cancers. These issues contribute to inaccuracies associated with HR estimation, and therefore, the pooling of results may produce bias and heterogeneity. As a result, the diversification of adjusted factors across studies along with a statistical

adjustment for the different clinicopathologic factors included in multivariate analysis might have contributed to the significant heterogeneity.

In addition, traditional survival analysis techniques (Kaplan-Meier, log-rank test) rely on variable dichotomisation into high or low values or splitting variables into multiple bins. In addition, cut-off point selection itself could potentially influence the prognostic value of the proposed association [47]. Due to the lack of a clear and widely agreed upon cut-off definition, the researchers preferred to arbitrarily create one themselves in the laboratory, so the cut-off point and the accuracy of the value varied between studies [24]. All of the above cases made the interpretation difficult because patients with the same values would be considered to have high miR-21 expression in some studies but low expression in

Figure 3 Begg's funnel plot of publication bias. Funnel plot for the visual assessment of the presence of publication bias associated with all of the studies included in the meta-analysis. The funnel graph plots the log of the hazard ratio (HR) against the standard error of the log of the HR (an indicator of the sample size). The open circles indicate the individual studies. The line in the centre represents the pooled HR. Egger's test for publication bias was not significant (p = 0.174).

others [64]. In essence, estimates derived from different tumour analyses are not comparable, not to mention that they should not be combined in a meta-analysis. Therefore, the assessment of miR-21 expression must be considered to be a potential source of heterogeneity. Thus, adopting a consensus cut-off value for miR-21 expression could facilitate the replication of results. For miR-21 to be a useful predictive biomarker in clinical practice, a single clearly defined protocol needs to be developed and validated to allow the comparison of outcomes across studies.

Although the Begg's test suggested a *p* value of 0.174, the funnel plot provides some slight evidence of asymmetry between the included studies, which indicates that some epidemiological research bias exists. We attempted to minimise publication bias by performing the literature search as completely as possible using PubMed and Chinese Biomedicine databases, without language or date of publication restrictions. However, limitations still existed as the total number of included studies and the total sample size were relatively small. In addition, we did not extend the search to unpublished data that would likely include increased proportions of null results. Positive results tend to be more acceptable by journals, whereas negative results are often rejected or are not even submitted for review. As already highlighted, the negative studies reported less detailed results, making them unlikely to be evaluated. What's more, the language of publication also introduced bias because positive results tend to be published in English-language journals. Although our search was conducted without language restriction, all of the studies included in the meta-analysis were published in

English. As is known to all, the line across the top of a funnel should be representative of the pooled effect.

Our study identified several limitations that must be addressed. First, inadequate sample size was a frequent problem in the studies included in our analyses, with only 15 of the 31 studies reporting outcomes from over 100 patients. While pooling data may in part address deficiencies in individual study sample size, smaller studies are more likely to generate heterogeneity, as we observed. Second, our study used data from published studies rather than individual patient data (IPD), which limited our ability to explore the potential for confounding by various demographic and clinical factors (e.g., ethnicity, disease stage, differentiation and treatment regimes). By contrast, IPD based meta-analysis can be used to analyse all of the data in a consistent manner and includes data from unpublished studies. A careful collaborative reanalysis of the raw data from several good studies may be more valuable than a more superficial review that mixes good and poor studies [64]. Additionally, this study was predominantly based on the findings of observational studies. In particular, a considerable portion of the included studies were retrospectively accrued cohorts, which inherently contained greater potential for confounding than do randomised controlled trials. This issue led to conflicting results and also influenced the authentic prognostic value of miR-21 alterations, providing a lower level of evidence than desired. In addition, four publications had a slightly shorter follow-up time with a duration less than three years. However, we found that in the Capodanno study (2013) and Bowell study (2013), the majority of patients were diagnosed with locally advanced disease. Pancreatic ductal adenocarcinoma (PDAC, Jamieson [38]) and astrocytoma (Zhi [37]), of which grade III and IV constitute 62% of cases, are two of the most aggressive malignancies. The prognosis of these patients is quite poor. Finally, quality assessment tools for examining prognostic and predictive biomarker studies do not currently exist [65], and published articles have often lacked sufficient information to allow an adequate assessment of the quality of the study or the generalisation of the study results. The quality of pooled studies significantly influences the level of confidence of meta-analyses. Therefore, we performed a methodological assessment of the studies to avoid including some poor quality studies in general instead of scoring each individual study [65] according to the REMARK method [25,27] and the explanation and elaboration that were recently published [66].

Conclusion
MiR-21 overexpression was found to be associated with decreased overall survival in patients with a wide variety of tumour categories in the present systematic review

with meta-analysis. As this research is limited to patients who received surgical treatment without any adjuvant therapy, the miR-21 expression status is a direct outcome of cancer itself and reflected the impact of miR-21 on cancer progression. Therefore, MiR-21 expression is a potentially useful biomarker for predicting prognosis and is a promising prognostic tool to help clinicians make difficult therapeutic decisions. In addition, although we excluded studies that did not include sufficient survival data, we noted that some of them contain negative conclusions about the prognostic role of miR-21. Therefore, large adequately designed prospective studies, both observational cohorts and clinical trials that employ standard methodology, are now urgently needed to substantiate our conclusions. The exact role of miR-21 expression needs to be determined by an appropriate multivariate analysis taking into account the classical well-defined prognostic factors for each type of cancer. Additionally, international consensus is urgently required to mandate a homogeneous miR-21 assessment methodology, to enable comparisons and the combination of large, prospectively planned individual patient data meta-analyses. These types of studies may help determine if miR-21 expression might be more appropriate and better used in clinical decision-making for tumour patients.

Additional files

Additional file 1: Table S1. Data extraction from the eligible studies.

Additional file 2: Table S2. The PRISMA Guideline for reporting this systematic review and meta-analysis.

Additional file 3: Figure S1. Sensitivity analysis of all of the studies.

Abbreviations

MiR-21: microRNA-21; OS: Overall survival; HR: Hazard ratio; 95% CI: 95% confidence interval; miRNAs: MicroRNAs; PDCD4: Programmed cell death 4; TPM1: Tropomyosin1; PTEN: Phosphatase and tensin homolog; MOOSE: Meta-analysis of Observational Studies in Epidemiology; qRT-PCR: Quantitative reverse-transcription polymerase chain reaction; CEA: Cut-off value; IPD: Individual patient data; PDAC: Pancreatic ductal adenocarcinoma; CRC: Colorectal cancer; NSCLC: Non-small cell lung cancer; HNSCC: Head and neck squamous cell carcinoma; CC: Colon cancer; RC: Rectal cancer; HCC: Hepatocellular carcinoma; ESCC: Oesophageal squamous cell carcinoma; BC: Breast cancer; RCC: Renal cell carcinoma; *: Duke's stage; ISH: In Situ Hybridisation; NG: Not given; &: Adjacent noncancerous tissues were procured from patients.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

The authors' contributions are as follows: BZ and QH were responsible for the concept and design of the study. JL and WW searched the databases according to the inclusion and exclusion criteria. WZ and RJ gave advice on the meta-analysis methodology. CG and WL helped extract quantitative data from some papers. JL and WW analysed the data. JL and WW wrote the draft of the paper. QH, BZ and RJ extensively reviewed and edited the manuscript. All of the authors were involved in interpretation of results and revision of the manuscript and approved the final version of the manuscript.

Author details

[1]Department of Preventive Medicine, School of Public Health, Sun Yat-sen University, Zhongshan II Road, Guangzhou 510080, PR China. [2]State Key Laboratory of Genetic Engineering, Centre for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai 200433, PR China. [3]Department of Toxicology, Guangzhou Centre for Disease Control and Prevention, Guangzhou 510440, PR China. [4]Department of Public Health Sciences, Karolinska Institutet, Stockholm 11668, Sweden.

References

1. Bartel DP: **MicroRNAs: genomics, biogenesis, mechanism, and function.** *Cell* 2004, **116**(2):281–297.
2. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F, Negrini M, Croce CM: **An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.** *Proc Natl Acad Sci U S A* 2004, **101**(26):9740–9744.
3. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: **Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.** *Proc Natl Acad Sci U S A* 2004, **101**(9):2999–3004.
4. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: **Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.** *Nat Rev Cancer* 2005, **433**(17):769–773.
5. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN: **Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.** *Cancer Cell* 2010, **18**(3):282–293.
6. Kent OA, Mendell JT: **A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.** *Oncogene* 2006, **25**(46):6188–6196.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: **A microRNA expression signature of human solid tumors defines cancer gene targets.** *Proc Natl Acad Sci U S A* 2006, **103**(7):2257–2261.
8. Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K, Mori M: **Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer.** *Int J Oncol* 2010, **36**(5):1089–1095.
9. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N: **Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.** *Cancer Sci* 2010, **101**(1):241–249.
10. Chan SH, Wu CW, Li AF, Chi CW, Lin WC: **miR-21 microRNA expression in human gastric carcinomas and its clinical association.** *Anticancer Res* 2008, **28**(2A):907–911.
11. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y: **Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.** *Biomed Pharmacother* 2010, **64**(6):399–408.
12. Li J, Huang H, Sun L, Yang M, Pan C, Chen W, Wu D, Lin Z, Zeng C, Yao Y, Zhang P, Song E: **MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.** *Clin Cancer Res* 2009, **15**(12):3998–4008.
13. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES: **Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.** *Clin Chem* 2008, **54**(10):1696–1704.
14. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA: **microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.** *Blood* 2010, **116**(6):945–952.
15. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F: **Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer.** *Lung Cancer* 2010, **67**(2):170–176.
16. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: **MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.** *Gastroenterology* 2007, **133**(2):647–658.

17. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY: **MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.** *Cell Res* 2008, **18**(3):350–359.

18. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y: **MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene.** *Oncogene* 2008, **27**(31):4373–4379.

19. Zhu S, Si ML, Wu H, Mo YY: **MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).** *J Biol Chem* 2007, **282**(19):14328–14336.

20. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H: **MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.** *Oncogene* 2008, **27**(15):2128–2136.

21. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS: **Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.** *Clin Chem* 2011, **57**(1):84–91.

22. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG: **Prognostic versus predictive value of biomarkers in oncology.** *Eur J Cancer* 2008, **44**(7):946–953.

23. Chen J, Wang X: **MicroRNA-21 in breast cancer: diagnostic and prognostic potential.** *Clin Transl Oncol* 2014, **16**(3):225–233.

24. Altman DG, Lausen B, Sauerbrei W, Schumacher M: **Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.** *J Natl Cancer Inst* 1994, **86**(11):829–835.

25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.** *J Clin Epidemiol* 2009, **62**(10):e1–e34.

26. Parmar MK, Torri V, Stewart L: **Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.** *Stat Med* 1998, **17**(24):2815–2834.

27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: **REporting recommendations for tumour MARKer prognostic studies (REMARK).** *Eur J Cancer* 2005, **41**(12):1690–1696.

28. Higgins JP, Thompson SG: **Quantifying heterogeneity in a meta-analysis.** *Stat Med* 2002, **21**(11):1539–1558.

29. Higgins JP, Thompson SG, Deeks JJ, Altman DG: **Measuring inconsistency in meta-analyses.** *BMJ* 2003, **327**(7414):557–560.

30. Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H: **Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.** *Mod Pathol* 2012, **25**(1):112–121.

31. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T: **Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.** *Oncology* 2010, **79**(3–4):313–320.

32. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ, Schlecht NF: **Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.** *Am J Pathol* 2009, **174**(3):736–745.

33. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: **MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.** *RNA* 2008, **14**(11):2348–2360.

34. Gao W, Shen H, Liu L, Xu J, Shu Y: **MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis.** *J Cancer Res Clin Oncol* 2011, **137**(4):557–566.

35. Lee JA, Lee HY, Lee ES, Kim I, Bae JW: **Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast.** *J Breast Cancer* 2011, **14**(4):269–275.

36. Jiang J, Zheng Y, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J: **Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.** *PLoS One* 2011, **6**(8):e23271.

37. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang CY, Zhang J, Yang Y: **The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.** *Eur J Cancer* 2010, **46**(9):1640–1649.

38. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA: **MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.** *Clin Cancer Res* 2012, **18**(2):534–545.

39. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC: **MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.** *JAMA* 2008, **299**(4):425–436.

40. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, Brunner N, Baker A, Moller S, Nielsen HJ: **High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients.** *Clin Exp Metastasis* 2011, **28**(1):27–38.

41. Faltejskova P, Besse A, Sevcikova S, Kubiczkova L, Svoboda M, Smarda J, Kiss I, Vyzula R, Slaby O: **Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells.** *Int J Colorectal Dis* 2012, **27**(11):1401–1408.

42. Chen TH, Chang SW, Huang CC, Wang KL, Yeh KT, Liu CN, Lee H, Lin CC, Cheng YW: **The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer.** *Colorectal Dis* 2013, **15**(11):1367–1374.

43. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A: **Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.** *J Natl Cancer Inst* 2013, **105**(12):849–859.

44. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK: **High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.** *Med Oncol* 2012, **29**(2):618–626.

45. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathe EA, Takenoshita S, Yokota J, Haugen A, Harris CC: **The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.** *Clin Cancer Res* 2011, **17**(7):1875–1882.

46. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E: **Clinical evaluation of microRNA expression profiling in non small cell lung cancer.** *Lung Cancer* 2013, **81**(3):388–396.

47. Hollander N, Sauerbrei W, Schumacher M: **Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint.** *Stat Med* 2004, **23**(11):1701–1713.

48. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D: **Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance.** *Mol Carcinog* 2013, **52**(4):297–303.

49. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR: **MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.** *PLoS One* 2013, **8**(8):e71978.

50. Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC: **Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.** *Cancer Res* 2013, **73**(13):3821–3832.

51. Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U: **The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer.** *Clin Cancer Res* 2013, **19**(14):3955–3965.

52. Capodanno A, Boldrini L, Proietti A, Ali G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A, Lucchi M, Mussi A, Fontanini G: **Let-7 g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.** *Int J Oncol* 2013, **43**(3):765–774.

53. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM: **The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.** *J Mol Diagn* 2012, **14**(4):385–392.

54. Kjaer-Frifeldt S, Hansen TF, Nielsen BS, Joergensen S, Lindebjerg J, Soerensen FB, de Pont Christensen R, Jakobsen A: **The prognostic importance of miR-21 in stage II colon cancer: a population-based study.** *Br J Cancer* 2012, **107**(7):1169–1174.

55. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC: **MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.** *Clin Cancer Res* 2009, **15**(19):6192–6200.

56. Wu L, Li G, Feng D, Qin H, Gong L, Zhang J, Zhang Z: **MicroRNA-21 expression is associated with overall survival in patients with glioma.** *Diagn Pathol* 2013, **8**:200.

57. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D: **Expression of microRNAs in patients with pancreatic cancer and its prognostic significance.** *Pancreas* 2013, **42**(1):67–71.

58. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E: **Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up.** *Clin Chem* 2014, **60**(1):197–205.

59. Valladares-Ayerbes M, Blanco M, Haz M, Medina V, Iglesias-Diaz P, Lorenzo-Patino MJ, Reboredo M, Santamarina I, Figueroa A, Anton-Aparicio LM, Calvo L: **Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer.** *Int J Oncol* 2011, **39**(5):1253–1264.

60. Windeler J: **Prognosis - what does the clinician associate with this notion?** *Stat Med* 2000, **19**(4):425–430.

61. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X, Zhao Y: **Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis.** *Eur J Clin Invest* 2011, **41**(11):1245–1253.

62. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CSR, Harris AL: **Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.** *Br J Haematol* 2008, **141**(5):672–675.

63. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Chiaro MD, Peters GJ, Giaccone G: **Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.** *PLoS One* 2010, **5**(5):e10630.

64. Altman DG: **Systematic reviews of evaluations of prognostic variables.** *BMJ* 2001, **323**(7306):224–228.

65. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: **Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.** *JAMA* 2000, **283**(15):2008–2012.

66. Altman DG, McShane LM, Sauerbrei W, Taube SE: **Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.** *PLoS Med* 2012, **9**(5):e1001216.